Overall, our findings revealed that GCDH K438 acetylation inhibits HCC progression through inhibition of the ATR–CHK1 axis and ROS-mediated activation of autophagy, highlighting its potential as a therapeutic strategy for preventing HCC progression (Fig. 9). This evidence concerns the gene CHEK1 and hepatocellular carcinoma.